Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Corifollitropin Alfa→

Corifollitropin Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
652990-24-4
Molecular formula
C945H1481N265O284S29
Molecular weight
~44000 g/mol
Drug class
Long-acting recombinant follicle-stimulating hormone (FSH) analogue
Mechanism of action
Binds and activates the FSH receptor on ovarian granulosa cells, promoting follicular growth and development. The carboxy-terminal peptide extension prolongs activity compared with conventional recombinant FSH.
Indications / reported uses
  • Controlled ovarian stimulation, in combination with a GnRH antagonist, for development of multiple follicles in women participating in an assisted-reproduction programme
  • EMA product information also includes selected adolescent males with hypogonadotropic hypogonadism in combination with hCG; verify the latest age wording and local label

Sources: EMA EPAR — Elonva · EMA product information (updated 30 Oct 2025) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Long-acting recombinant follicle-stimulating hormone (FSH) analogue

Mechanism of action

Binds and activates the FSH receptor on ovarian granulosa cells, promoting follicular growth and development. The carboxy-terminal peptide extension prolongs activity compared with conventional recombinant FSH.

General use cases

  • Controlled ovarian stimulation, in combination with a GnRH antagonist, for development of multiple follicles in women participating in an assisted-reproduction programme
  • EMA product information also includes selected adolescent males with hypogonadotropic hypogonadism in combination with hCG; verify the latest age wording and local label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Corifollitropin Alfa Environmental Risk Assessment (ERA) (the Corifollitropin Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.